Literature DB >> 18403594

Molecular characterization of human breast tumor vascular cells.

Rajendra Bhati1, Cam Patterson, Chad A Livasy, Cheng Fan, David Ketelsen, Zhiyuan Hu, Evangeline Reynolds, Catherine Tanner, Dominic T Moore, Franco Gabrielli, Charles M Perou, Nancy Klauber-DeMore.   

Abstract

A detailed understanding of the assortment of genes that are expressed in breast tumor vessels is needed to facilitate the development of novel, molecularly targeted anti-angiogenic agents for breast cancer therapies. Rapid immunohistochemistry using factor VIII-related antibodies was performed on sections of frozen human luminal-A breast tumors (n = 5) and normal breast (n = 5), followed by laser capture microdissection of vascular cells. RNA was extracted and amplified, and fluorescently labeled cDNA was synthesized and hybridized to 44,000-element long-oligonucleotide DNA microarrays. Statistical analysis of microarray was used to compare differences in gene expression between tumor and normal vascular cells, and Expression Analysis Systematic Explorer was used to determine enrichment of gene ontology categories. Protein expression of select genes was confirmed using immunohistochemistry. Of the 1176 genes that were differentially expressed between tumor and normal vascular cells, 55 had a greater than fourfold increase in expression level. The extracellular matrix gene ontology category was increased while the ribosome gene ontology category was decreased. Fibroblast activation protein, secreted frizzled-related protein 2, Janus kinase 3, and neutral sphingomyelinase 2 proteins localized to breast tumor endothelium as assessed by immunohistochemistry, showing significantly greater staining compared with normal tissue. These tumor endothelial marker proteins also exhibited increased expression in breast tumor vessels compared with that in normal tissues. Therefore, these genetic markers may serve as potential targets for the development of angiogenesis inhibitors.

Entities:  

Mesh:

Year:  2008        PMID: 18403594      PMCID: PMC2329846          DOI: 10.2353/ajpath.2008.070988

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Genes expressed in human tumor endothelium.

Authors:  B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

Review 2.  Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells.

Authors:  Hubertus P A Jersmann
Journal:  Immunol Cell Biol       Date:  2005-10       Impact factor: 5.126

3.  Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.

Authors:  Ronald J Buckanovich; Dimitra Sasaroli; Ann O'brien-Jenkins; Jeffrey Botbyl; Josè R Conejo-Garcia; Fabian Benencia; Lance A Liotta; Phyllis A Gimotty; George Coukos
Journal:  Cancer Biol Ther       Date:  2006-06-09       Impact factor: 4.742

4.  Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression.

Authors:  Jia-Lin Lee; Ching-Jin Chang; Ling-Ling Chueh; Chung-Tien Lin
Journal:  Breast Cancer Res Treat       Date:  2006-06-22       Impact factor: 4.872

5.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

6.  Hep27, a member of the short-chain dehydrogenase/reductase family, is an NADPH-dependent dicarbonyl reductase expressed in vascular endothelial tissue.

Authors:  N Shafqat; J Shafqat; G Eissner; H-U Marschall; K Tryggvason; U Eriksson; F Gabrielli; H Lardy; H Jörnvall; U Oppermann
Journal:  Cell Mol Life Sci       Date:  2006-05       Impact factor: 9.261

7.  Tumor vascular proteins as biomarkers in ovarian cancer.

Authors:  Ronald J Buckanovich; Dimitra Sasaroli; Anne O'Brien-Jenkins; Jeffrey Botbyl; Rachel Hammond; Dionysios Katsaros; Raphael Sandaltzopoulos; Lance A Liotta; Phyllis A Gimotty; George Coukos
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

8.  Analysis of membrane topology of neutral sphingomyelinase 2.

Authors:  Motohiro Tani; Yusuf A Hannun
Journal:  FEBS Lett       Date:  2007-03-01       Impact factor: 4.124

Review 9.  Drug insight: VEGF as a therapeutic target for breast cancer.

Authors:  Bryan P Schneider; George W Sledge
Journal:  Nat Clin Pract Oncol       Date:  2007-03

Review 10.  The role of dendritic cell precursors in tumour vasculogenesis.

Authors:  G Coukos; F Benencia; R J Buckanovich; J R Conejo-Garcia
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

View more
  56 in total

1.  Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Authors:  Paul B Romesser; David H Perlman; Douglas V Faller; Catherine E Costello; Mark E McComb; Gerald V Denis
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

2.  TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling.

Authors:  A Fiorio Pla; H L Ong; K T Cheng; A Brossa; B Bussolati; T Lockwich; B Paria; L Munaron; I S Ambudkar
Journal:  Oncogene       Date:  2011-06-20       Impact factor: 9.867

Review 3.  Harnessing systems biology approaches to engineer functional microvascular networks.

Authors:  Lauren S Sefcik; Jennifer L Wilson; Jason A Papin; Edward A Botchwey
Journal:  Tissue Eng Part B Rev       Date:  2010-06       Impact factor: 6.389

Review 4.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 5.  Targeting angiogenesis and the tumor microenvironment.

Authors:  Jennifer Samples; Monte Willis; Nancy Klauber-Demore
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

6.  Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.

Authors:  Petr Busek; Eva Balaziova; Ivana Matrasova; Marek Hilser; Robert Tomas; Martin Syrucek; Zuzana Zemanova; Evzen Krepela; Jaromir Belacek; Aleksi Sedo
Journal:  Tumour Biol       Date:  2016-08-04

7.  Novel surface targets and serum biomarkers from the ovarian cancer vasculature.

Authors:  Dimitra Sasaroli; Phyllis A Gimotty; Harsh B Pathak; Rachel Hammond; Eleni Kougioumtzidou; Dionyssios Katsaros; Ron Buckanovich; Karthik Devarajan; Raphael Sandaltzopoulos; Andrew K Godwin; Nathalie Scholler; George Coukos
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

8.  Frizzled-5: a high affinity receptor for secreted frizzled-related protein-2 activation of nuclear factor of activated T-cells c3 signaling to promote angiogenesis.

Authors:  Yuri K Peterson; Patrick Nasarre; Ingrid V Bonilla; Eleanor Hilliard; Jennifer Samples; Thomas A Morinelli; Elizabeth G Hill; Nancy Klauber-DeMore
Journal:  Angiogenesis       Date:  2017-08-24       Impact factor: 9.596

9.  Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal.

Authors:  Bing Zhou; Jeffrey S Damrauer; Sean T Bailey; Tanja Hadzic; Youngtae Jeong; Kelly Clark; Cheng Fan; Laura Murphy; Cleo Y Lee; Melissa A Troester; C Ryan Miller; Jian Jin; David Darr; Charles M Perou; Ross L Levine; Maximilian Diehn; William Y Kim
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

10.  Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Authors:  Chunsheng Li; Ann-Marie Chacko; Jia Hu; Kosei Hasegawa; Jennifer Swails; Luigi Grasso; Wafik S El-Deiry; Nicholas Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  Cancer Biol Ther       Date:  2014-02-19       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.